Dropped Head Syndrome: Report of Three Cases During Treatment with a Mek Inhibitor
Neurol 79:1929-1932, Chen, X.,et al, 2012
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
PML-IRIS in a patient treated with Brentuximab
Neurol 79:2075-2077, Geldern, G.,et al, 2012
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomized controlled trial
Lancet 380:1749-1758, Lopes, R.,et al, 2012
Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
Stroke 43:3442-3453, Furie, K.,et al, 2012
Bleeding During Treatment with Aspirin Versus Apixaban in Patients with Atrial Fibrillation Unsuitable for Warfarin
Stroke 43:3291-3297, Flaker, G.,et al, 2012
Nonvitamin K-Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack
Stroke 43:3298-3304, Ntaios, G.,et al, 2012
Dopa-Responsive Dystonia Revisited
Arch Neurol 69:1558-1562, Tadic, V.,et al, 2012
Myasthenia Gravis
BMJ 345:e8497, Spillane, J.,et al, 2012
Statin Use During Ischemic Stroke Hospitalization is Strongly Associated with Improved Poststroke Survival
Stroke 43:147-154, Flint, A.C.,et al, 2012
Using Dabigatran in Patients with Stroke A Practical Guide for Clinicians
Stroke 43:271-279, Alberts, M.J.,et al, 2012
Long-lasting Treatment Effect of Rituximab in MuSK Myasthenia
Neurol 78:189-193, Diaz-Manera,J.,et al, 2012
Sporadic Cerebral Amyloid Angiopathy Revisited: Recent Insights Into Pathophysiology and Clinical Spectrum
JNNP 83:124-137, Charidimou,A.,et al, 2012
Statins and Intracerebral Hemorrhage
Arch Neurol 69:39-45,13, Hackam,D.G,et al, 2012
New Antithrombotic Drugs for Atrial Fibrillation: Caution is Needed
Lancet 379:e24, Bell,S.,et al, 2012
Anticoagulant Loses its Lustre
Lancet 379:301, Mullar,A., 2012
Natalizumab-Associated PML Identified in the Presymptomatic Phase Using MRI Surveillance
Neurol 78:507-508, Blair,N.F.,et al, 2012
Fatal PML Associated with Efalizumab Therapy
Neurol 78:458-467, Schwab,N.,et al, 2012
Stiff-Man Syndrome and Variants
Arch Neurol 69:230-238, McKeon,A.,et al, 2012
The Argatroban and Tissue-Type Plasminogen Activator Stroke Study
Stroke 43:770-775,623, Barreto,A.D.,et al, 2012
Cost-Effectiveness of Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack
Stroke 43:881-883, Kamel,H.,et al, 2012
Critique of Apixaban Versus Warfarin in Patients with Atrial Fibrillation
Stroke 43:922-923, Nedeltchev,K, 2012
Clinicopathologic Conference,Necrotizing Noninflammatory Myopathy Consistent with Exposure to Statins
NEJM 36:944-954, Case 7-2012, 2012
Donepezil and Memantine for Moderate-to Severe Alzheimers Disease
NEJM 366:893-903,957, Howard,R.,et al, 2012
A Randomized, Double-Blind, Placebo-Controlled Trial of Antidepressants in Parkinson Disease
Neurol 78:1229-1236, Richard,I.H.,et al, 2012
Update on the Pathophysiology and Management of Idiopathic Intracranial Hypertension
JNNP 83:488-494, Biousse,V.,et al, 2012
Progress for Stroke Prevention with Atrial Fibrillation
Stroke 43:1179-1185, Katsnelson,M.,et al, 2012
Sildenafil-Induced Cervical Spinal Cord Infarction
AJNR 33:e32-e33, Walden,J.E. & Castillo,M., 2012
Treatment of Behcets Disease
UpToDate, Jan, Smith, E.L. & Yazici, Y., 2012
Autoimmune Epilepsy
Arch Neurol 69:582-593,565, Quek, A.M.L.,et al, 2012
Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack
NEJM 366:1914-1922;, Davis, S.M. & Donnan, G.A., 2012
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Herpes Encephalitis During Natalizumab Tretament in Multiple Sclerosis
Mult Scler J 18:909-911, Kwiatkowski, A.,et al, 2012
Late onset autism and anti-NMDA-receptor encephalitis
Lancet 378:98;378, Creten, C.,et al, 2011
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 69:1060-1062, Phan-Ba, R.,et al, 2011
Apixaban in Atrial Fibrillation From Bleeding Cows to 21st Century Medicinal Chemistry
Stroke 42:2376-2378, Cucchiara, B.L.,et al, 2011
Weighing the Benefits of High-Dose Simvastatin against the Risk of Myopathy
NEJM 365:285-287, Egan, A.,et al, 2011
Apixaban in Patients With Atrial Fibrillation
NEJM 364:806-817, Connolly,S.J.,et al, 2011
GABAB Receptor Antibodies in Limbic Encephalitis and Anti-GAD-Associated Neurologic Disorders
Neurol 76:795-800, Boronat,A.,et al, 2011
Effectiveness of Adding Memantine to an Alzheimer Dementia Treatment Regimen Which Already Includes Stable Donepezil Therapy: A Critically Appraised Topic
The Neurologist 17:121-123, Riordan,K.C.,et al, 2011
Rituximab Monotherapy for Patients With Recurrent Primary CNS Lymphoma
Neurol 76:929-930, Batchelor,T.T.,et al, 2011
Rituximab in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Report of 13 Cases and Review of the Literature
JNNP 82:306-308, Benedetti,L.,et al, 2011
Percutaneous Vascular Interventions for Acute Ischemic Stroke
Stroke 42:e31-e32, ORourke,K.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Arch Neurol 68:186-191, Miravalle,A.,et al, 2011
Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Arch Neurol 68:165-171, Bronstein,J.M.,et al, 2011
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
Neurol 76:1697-1704, Vermersch,P.,et al, 2011
The use of rituximab in myasthenia gravis and Lambert--Eaton myasthenic syndrome
JNNP 82:671-673, Maddison, P.,et al, 2011
Use and monitoring of low dose rituximab in myasthenia gravis
JNNP 82:659-663, Blum, S., et al, 2011
Statin Use Following Intracerebral Hemorrhage
Arch Neurol 68:573-579, Westover, M.B.,et al, 2011
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011